

Reference: FOI.ICB-2627/224

Subject: High Cost Drug Commissioning

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
1. Please can you indicate how you currently assure appropriate use of NHS Payment Scheme Annex A (High Cost) Drugs (HCD) for your patients receiving treatment via NHS provider trusts (Please put a tick or a cross by all that apply and provide additional text where indicated) a. Blueteq® b. Other database software (please specify product used) c. ICB employed staff imbedded into provider trust organisation providing patient-level assurance to ICB d. ICB funding to provider trusts for assurance activities e.g. clinical audit (please provide a summary of your assurance process) e. Assurance is through monitoring monthly spend against agreed HCD budget f. Other/none, (please specify mechanism used, if any)	In Bristol, North Somerset & South Gloucestershire ICB the assurance of appropriate use of HCD is through the following options: A, e and f F: ICB funding to provider trust organisation to employ pharmacists to provide patient-level assurance to ICB

2. If using a bought in software product for HCD commissioning, please state month and year of next renewal date	September 2027
3. Within the next 12 months, are you planning a review and assessment of your current HCD commissioning assurance processes (and products) to appraise options for future HCD commissioning?	Yes, possibly.

The information provided in this response is accurate as of 15 September 2026 and has been approved for release by Matt Backler, Director of Operational Finance for NHS Bristol, North Somerset and South Gloucestershire ICB.